Histological evolution of hepatitis C virus infection after renal transplantation

Background information regarding histological progression of hepatitis C after renal transplant (RTx) is scarce. Aims To analyze clinical and laboratory evolution and histological progression of hepatitis C in patients evaluated before and after RTx. Methods Twenty‐two HCV‐infected patients submitte...

Full description

Saved in:
Bibliographic Details
Published in:Clinical transplantation Vol. 26; no. 6; pp. 842 - 848
Main Authors: de Oliveira Uehara, Silvia Naomi, Emori, Christini Takemi, Pereira, Patrícia da Silva Fucuta, Perez, Renata M., Pestana, José Osmar Medina, Lanzoni, Valéria Pereira, Silva, Ivonete Sandra Souza e, Silva, Antonio Eduardo Benedito, Ferraz, Maria Lucia Cardoso Gomes
Format: Journal Article
Language:English
Published: Hoboken, NJ Blackwell Publishing Ltd 01-11-2012
Wiley
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background information regarding histological progression of hepatitis C after renal transplant (RTx) is scarce. Aims To analyze clinical and laboratory evolution and histological progression of hepatitis C in patients evaluated before and after RTx. Methods Twenty‐two HCV‐infected patients submitted to liver biopsy pre‐ and post‐RTx were included. A semiquantitative analysis of necroinflammatory activity and fibrosis staging was performed and the two biopsies were compared. Results Patients were mostly men (73%) with mean age of 36 ± 9 yr. Time post‐transplant was 4 ± 2 yr and time between biopsies was 5 ± 2 yr. An elevation of alanine aminotransferase (p = 0.041) and aspartate aminotransferase (p = 0.004) levels was observed in the post‐transplant period. Fibrosis progression after renal transplantation was observed in 11 (50%) of the patients, and necroinflammatory activity worsening was observed in 7 (32%) of the patients. The histological progression occurred even among those without significant histological lesions in pre‐transplant biopsy. Conclusion The findings of this study suggest that the practice of indicating treatment in the pre‐transplant phase based mainly on histological disease should be revised, because a high proportion of patients present disease progression. Because interferon cannot be used safely after RTx, treatment should be indicated for all ESRD patients with hepatitis C.
Bibliography:ark:/67375/WNG-LBKVLPDK-K
ArticleID:CTR1635
istex:423A7A816C9B8A7B0FB504AB88D2CAD5AB064691
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0902-0063
1399-0012
DOI:10.1111/j.1399-0012.2012.01635.x